MacroGenics IncHere is the public summary page for MacroGenics Inc. Please login to see the complete information for MacroGenics Inc including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how MacroGenics Inc stacks up relative to its peers. |
| Darwin Score | -24 |
| Ticker | MGNX |
| Latest Price | 1.52 USD as of close on 16-Jul-2025 |
| 3 Month price range | 1.19 to 1.79 USD |
| Market Capitalisation | 99.68Mn USD |
| Country | United States of America |
| Region | North America |
| Economic Sector | Health Care |
| Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Sub-Industry | Biotechnology |
| Description | MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland. See More ... |
| Company URL | https://www.macrogenics.com |
| See Darwins Full Analysis for MacroGenics Inc |
Tell Me About
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for MacroGenics Inc. Further information and full detail is available when you login.
| TMA Part | Focus of Analysis | TMA Score |
|---|---|---|
| Price | Analysis of performance, trend, RSI, OBV and moving averages | -7 |
| Sentiment | News and Candle Patterns. | -1 |
| Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | +1 |
| Flow | Institutional, Fund and Insider buying and selling. | 0 |
| Models | Forecast models. | -17 |
Alerts
There are 7 live alerts for MacroGenics Inc.
- Oversold - The 5 month RSI is +24.8. (Positive)
- Candle Pattern :: Inverted Hammer (Bearish) (Negative) (Negative)
- Divergence: Px Down & 15d RSI Up last 20 days. This alert has occurred 57 times over the last last year. The average forward returns are 2.4% over 5 days, 1.1% over 10 days, -5.9% over 15 days and -11.6% over 20 days. (Positive)
- Divergence: Px Down & OBV Up last 20 days. This alert has occurred 163 times over the last last year. The average forward returns are -0.3% over 5 days, -0.6% over 10 days, -3.5% over 15 days and -7.3% over 20 days. (Positive)
- Price crossing down through 5 day SMA. This alert has occurred 30 times over the last last year. The average forward returns are -2.3% over 5 days, -5.0% over 10 days, -7.0% over 15 days and -11.9% over 20 days. (Positive)
- Divergence: Px Down & 30d RSI Up last 20 days. This alert has occurred 51 times over the last last year. The average forward returns are -0.3% over 5 days, -2.6% over 10 days, -8.1% over 15 days and -12.7% over 20 days. (Positive)
- Cross Over (Down): 5dma . This alert has occurred 30 times over the last last year. The average forward returns are -2.3% over 5 days, -5.0% over 10 days, -7.0% over 15 days and -11.9% over 20 days. (Negative)
Peer Comparison
There are 22 peers of MacroGenics Inc.
| Asset Name | Industry Group | Asset Score |
|---|---|---|
| ACADIA Pharmaceuticals Inc (ACAD) | Biotechnology | +23 |
| Amgen Inc (AMGN) | Biotechnology | +42 |
| Arrowhead Pharmaceuticals Inc (ARWR) | Biotechnology | +9 |
| BioMarin Pharmaceutical Inc (BMRN) | Biotechnology | -5 |
| Biogen Inc (BIIB) | Biotechnology | -8 |
| Black Diamond Therapeutics Inc (BDTX) | Biotechnology | +5 |
| Dynavax Technologies Corp (DVAX) | Biotechnology | -4 |
| Exelixis Inc (EXEL) | Biotechnology | +43 |
| FibroGen Inc (FGEN) | Biotechnology | +1 |
| Gilead Sciences Inc (GILD) | Biotechnology | +11 |
| Halozyme Therapeutics Inc (HALO) | Biotechnology | +21 |
| Humacyte Inc (HUMA) | Biotechnology | -29 |
| Incyte Corp (INCY) | Biotechnology | -6 |
| Krystal Biotech Inc (KRYS) | Biotechnology | +3 |
| Moderna Inc (MRNA) | Biotechnology | -7 |
| Myriad Genetics Inc (MYGN) | Biotechnology | -25 |
| Neurocrine Biosciences Inc (NBIX) | Biotechnology | +27 |
| OPKO Health Inc (OPK) | Biotechnology | -5 |
| Regeneron Pharmaceuticals Inc (REGN) | Biotechnology | -9 |
| United Therapeutics Corp (UTHR) | Biotechnology | -10 |
| Vertex Pharmaceuticals Inc (VRTX) | Biotechnology | +12 |
| Vir Biotechnology Inc (VIR) | Biotechnology | -23 |
Share 
